Stress Hormone Testing

by Dr. Clark Hansen, NMD | Sep 11, 2008

A non-invasive urine sample can be used to evaluate your key neurohormones including the calming neurohormones Serotonin and GABA as well as the excitatory neurohormones Epinephrine, Norepinephrine and Dopamine. These five key neurohormones maintain the body’s balance of mood and focus. Chronic stress can deplete Serotonin and GABA, the calming neurohormones and raise your excitatory neurohormones leading to anxiety, high blood pressure, ulcers, depression and more.

Evaluation of these stress biomarkers can help you identify how stress is affecting your health. By correcting the imbalances you can reduce and eliminate fatigue, insomnia, anxiety, and depression, heart palpitations, high blood pressure, high blood sugar, headaches, migraines, ulcers, Fibromyalgia, ADD/ADHD, and improve immune function.

Indications

Stress, Nervousness, Anxiety
Obsessive Compulsive Behavior
Addictions
Sadness
Depression
Fibromyalgia
Attention Deficit / Hyperactivity Disorder
Muscle Tension
Heart Palpitations
High Blood Pressure
Migraines
Ulcers

Epinephrine

Epinephrine (Adrenalin) is secreted by the adrenal medulla in response to stress, low blood glucose, and exercise. It causes the breakdown of gylcogen in the liver, the release of fatty acids from the adipose (fat) tissue, vasodilation of the small arteries within muscle, and increases cardiac output.

Excess amounts can cause increased heart rate, elevated blood pressure (mainly systolic), high blood sugar, muscle soreness and suppressed immunity. Epinephrine is a neurotransmitter in the brain and also a major hormone in the body. Epinephrine is synthesized from Norepinephrine by enzymatic conversion.

Norepinephrine

Norepinephrine (Noradrenalin) is the primary excitatory neurotransmitter in the sympathetic nervous system and larger amounts are stored in the adrenal medulla. Nervous impulses from the sympathetic nervous system provide signals to the skin, heart, eyes, lungs, and GI system. Additionally, Norepinephrine plays a role in blood pressure, insulin resistance, and appetite control.

Like Epinephrine, excess amounts can cause increased heart rate, elevated blood pressure (mainly systolic), high blood sugar, muscle soreness and suppressed immunity. Norepinephrine is made from Dopamine.

Dopamine

Dopamine is a key regulatory neurotransmitter in the brain. It is a precursor to Norepinephrine. Excessive levels can cause anxiety and severe emotional disturbances, while a deficiency can cause attention problems and cognitive slowing. Severe deficiencies can cause Parkinson’s Disease. Dopamine is produced from the amino acid L-Tyrosine.

Serotonin

Serotonin is a calming neurotransmitter synthesized from the amino acid Tryptophan and the intermediate hormone 5-Hydroxytryptophan (5-HTP) by neurons in the brain as well as specialized cells in the gut, and lungs. Serotonin increases the dilation of blood vessels and plays a very important role in regulating appetite and mood. Deficiencies are associated with depression, anxiety, panic, obsessions, compulsions, food cravings and bulimia.

GABA

GABA is the primary inhibitory neurotransmitter in the brain. Stress and high levels of the excitatory neurohormones trigger increased GABA levels. GABA is often high in patients experiencing sleeping problems, nervousness, anxiety, hyperactivity, and seizure disorders.

Call for More Information

To learn more about Neurohormone testing or to inquire about scheduling an appointment with Dr. Hansen please call our office at 480-991-5092.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Click Here to see the full Report of the Research